JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial

Author:

Tuttle Katherine R123,Brosius Frank C45,Adler Sharon G6,Kretzler Matthias4,Mehta Ravindra L7,Tumlin James A8,Tanaka Yoshiya9,Haneda Masakazu10,Liu Jiajun11,Silk Maria E11,Cardillo Tracy E11,Duffin Kevin L11,Haas Joseph V11,Macias William L11,Nunes Fabio P11,Janes Jonathan M11

Affiliation:

1. Providence Health Care, Spokane, WA, USA

2. The Kidney Research Institute, Division of Nephrology, University of Washington School of Medicine, Seattle, WA, USA

3. The Institute of Translational Health Sciences, University of Washington School of Medicine, Seattle, WA, USA

4. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

5. Department of Internal Medicine, University of Arizona College of Medicine, Tucson, AZ, USA

6. Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center, Torrance, CA, USA

7. Division of Nephrology, University of California, San Diego, CA, USA

8. University of Tennessee College of Medicine, Chattanooga, TN, USA

9. The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

10. Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan

11. Eli Lilly and Company, Indianapolis, IN, USA

Funder

Eli Lilly and Company and Incyte Corporation

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3